Gene Therapy
Amsterdam Molecular Therapeutics BV receives global rights to develop and commercialize AMT-020 for acute intermittent porphyria
Published in Gene Therapy Weekly, March 22nd, 2007
The licence allows AMT to initiate the clinical development of AMT-020 to treat acute intermittent porphyria.
This follows successful collaboration between CIMA and AMT, demonstrating the safety and preclinical efficacy of the product, AMT-020. AMT-020 is an AAV vector gene therapy containing the porphobilinogen...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
Source: Gene Therapy Weekly (2007-03-22)
More Articles from Gene Therapy Weekly
- Drug Delivery
New Study Titled Drug Delivery Systems Estimates That the US Drug Delivery Market Value Might Reach Nearly $85 Billion By 2010 - Gene Therapy
Sigma-Aldrich Launches MISSION siRNA Druggable Genome Libraries - Patents
INEX and Alnylam Announce Allowance of New U.S. Patent Covering Delivery of RNAi Therapeutics - Patents
New Targeted Genetics Patent Provides Broad Coverage of Vectors Based on AAV Serotype 1 - Cancer Gene Therapy
Data on cancer gene therapy described by investigators at Chiba Cancer Center Research Institute, Division of Pathology - Cancer Gene Therapy
Data on cancer gene therapy detailed by researchers at Uppsala University, Immunology Division - More from this issue of Gene Therapy Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
